Related Experiment Videos
[Long-term antithrombotic treatment in patients with valve prostheses. Practical management and complications]
Insights
Patients with mechanical heart valve prostheses face 3-9% annual risks of bleeding or clotting complications. Optimal anticoagulant therapy selection balances prosthesis type, location, and individual patient risk factors for effective prevention.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Anticoagulant therapy is crucial for patients with mechanical and bioprosthetic heart valves to prevent thromboembolic and hemorrhagic complications.
- The annual risk of such complications varies based on prosthesis type (mitral, aortic, or combined) and location.
Purpose:
- To outline the risks associated with anticoagulant use in patients with heart valve prostheses.
- To provide guidance on selecting appropriate anticoagulant strategies based on prosthesis type, location, and individual patient risk.
- To discuss specific considerations for bioprostheses and complex patient scenarios.
Summary:
- Mechanical prostheses carry a 3-9% annual risk of thrombo-embolic and hemorrhagic complications, necessitating careful drug selection.
- Anti-vitamin K drugs combined with dipyridamole offer effective thrombo-embolic prevention for mechanical prostheses with controlled hemorrhagic risk.
- For bioprostheses, anticoagulant treatment (anti-vitamin K or anti-platelet) is recommended for 3-6 months post-operation, with prolonged anti-vitamin K use reserved for high-risk patients.
Impact:
- Informs clinical decision-making for optimizing anticoagulant therapy in heart valve prosthesis recipients.
- Highlights the need for individualized treatment plans to minimize complications.
- Identifies areas requiring further research, such as managing anticoagulation in pregnant patients or those undergoing procedures.
Abstract:
The cumulative annual risk of thrombo-embolic and haemorrhagic complications due to anticoagulants in patients with mechanical prostheses is in the order of 3 to 9 p. cent for mitral prostheses and mitral and aortic prostheses and 2 to 5 p. cent for aortic prostheses. Anticoagulant drugs should be chosen in terms of the type and the site of the implanted prosthesis and the coefficient of the thrombo-embolic and haemorrhagic risk of each subject. In patients with mechanical prostheses, the most effective prevention of the thrombo-embolic risk is ensured by the anti-vitamin K drugs associated with dipyridamole, with a low haemorrhagic risk if the treatment is correctly controlled. In patients with bioprostheses, the anticoagulant treatment (anti-vitamin K or anti-platelet drugs) should be maintained for three to six months after the operation; the anti-vitamin K drugs should not be prolonged indefinitely, except in patients at high risk of thrombo-embolism (atrial fibrillation with a very dilated left auricle, in particular). The management of a pregnant woman with a valve prosthesis and the problems of patients with prostheses undergoing extracardiac or dental operations or invasive investigations are still open to discussion.